U.S. Antimony: China's Kick Sparks Hope, But Execution Lags

What happened

China's 2024 antimony export restrictions provided a strong geopolitical catalyst for U.S. domestic producer U.S. Antimony, but the company's response has been slow to materialize in financial results. Despite securing a major DLA contract and a $27 million DPA grant, UAMY reported zero DLA revenue in Q1 2026, a net loss of $11.3 million, and operating cash burn of $12.1 million. The critical Thompson Falls expansion—expected to 'more than triple' capacity—is still not commissioned as of mid-May 2026, with management promising it will come online 'over the next few weeks.' Inventories have ballooned to $22 million, raising the risk of a price-cost mismatch if sales cadence slips, while insiders sold significant shares in late March at prices near $9-$10. The stock's 225% run-up over the past year prices in a successful ramp, but the underlying data shows that the step-change in revenue and margins remains unproven.

Implication

At $8.61, UAMY trades at a market cap of $1.37 billion, yet it generated only $6.8 million in revenue and a net loss of $11.3 million in Q1 2026. The bullish thesis relies entirely on the Thompson Falls expansion ramping up successfully and DLA deliveries converting to recognized revenue in the second half of 2026. However, the company is burning cash at a rate of over $12 million per quarter in operations alone, and inventory buildup suggests a potential mismatch between production and sales. Insider selling concentrated in late March, when the stock was around $9-10, suggests that those closest to the business are taking profits ahead of the execution test. Until Q2 or Q3 filings show explicit, sustained throughput and the first DLA revenue recognition, the risk-reward is unfavorable with a bear case value of $5.00.

Thesis delta

The narrative has shifted from 'geopolitical catalyst + contract wins' to 'execution-dependent test' as China's restrictions fade from the immediate news cycle and the company must now deliver on its operational promises. The market's attention is now on commissioning timing and DLA acceptance, with multiple insiders signaling skepticism through recent sales. This reduces the probability of a near-term upside surprise and increases the chance of disappointment if milestones slip.